



## CORRIGENDUM

# Corrigendum to: Effects of agomelatine and mirtazapine on sleep disturbances in major depressive disorder: evidence from polysomnographic and resting-state functional connectivity analyses

Wei-Feng Mi, Serik Tabarak, Li Wang, Su-Zhen Zhang, Xiao Lin, Lan-Ting Du, Zhen Liu, Yan-Ping Bao, Xue-Jiao Gao, Wei-Hua Zhang, Xue-Qin Wang, Teng-Teng Fan, Ling-Zhi Li, Xiao-Nan Hao, Yi Fu, Ying Shi, Li-Hua Guo, Hong-Qiang Sun, Lin Liu, Tian-Mei Si, Hong-Yan Zhang, Lin Lu and Su-Xia Li

In the originally published version of this manuscript, several errors were noted and listed in this corrigendum.

Upon the original publication, the affiliation “Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Haidian, Beijing, China” was omitted from author Lin Lu’s affiliation.

Upon the original publication, the following sentences in the “Materials and Methods” section, under the heading “Participants” should read:

“The depressed patients were randomly divided into two groups: agomelatine monotherapy (25 mg/tablet, manufactured by Servier) and mirtazapine monotherapy (30 mg/tablet, manufactured by N.V. Organon).”

“The patients took a fixed dose of one tablet of agomelatine or mirtazapine per day at 8:00 pm for the first 2 week after enrollment.”

These have now been corrected online.